BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Monogram Signs Deal With Pfizer, Out-Licenses Assay
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Monogram Signs Deal With Pfizer, Out-Licenses Assay
May 9, 2006
By
Karen Carey
No Comments
In addition to making a $25 million investment in Monogram Biosciences Inc., Pfizer Inc. agreed to globally license Monogram's HIV Co-Receptor Tropism Assay to aid in the clinical development of its CCR5 antagonist maraviroc. (BioWorld Today)
BioWorld